Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
Sumitomo Pharma suffered its bottom-line dipping into the red ink in the first half of FY2022 as it booked an impairment loss of 54.4 billion yen following the forecast review of Kynmobi (apomorphine), a Parkinson’s med floundering in the US.…
To read the full story
Related Article
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
May 16, 2023
- Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
February 1, 2023
- Sumitomo Braced for Red Ink to Continue in FY2023 on Latuda LOE
November 1, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- Sumitomo Pharma Likely to Miss 5-Year Biz Targets as COVID Hobbles US Launches
May 16, 2022
- Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
May 16, 2022
- Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
February 1, 2022
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
BUSINESS
- Tepezza, Trodelvy, and More Drugs Now Available in Japan; Kisunla Due Out on Nov. 26
November 21, 2024
- MM Drug Talquetamab Filed in Japan: J&J
November 21, 2024
- Terumo Puts Brake on Supply of Anapeine Generics
November 21, 2024
- Otsuka Plans US Filing of IgA Nephropathy Drug in H1 2025
November 20, 2024
- 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…